ACM
CYTK icon

Atika Capital Management’s Cytokinetics CYTK Stock Holding History

Atika Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,000
Closed -$4.91M – 99
2024
Q1 		$4.91M Buy
70,000
+19,000
+37% +$1.47M 0.48% 71
2023
Q4 		$4.26M Buy
+51,000
New +$1.85M 0.57% 61
2023
Q2 		– Sell
-75,063
Closed -$2.64M – 91
2023
Q1 		$2.64M Buy
75,063
+9,063
+14% +$370K 0.39% 62
2022
Q4 		$3.02M Sell
66,000
-94,310
-59% -$4.06M 0.43% 54
2022
Q3 		$7.77M Buy
160,310
+33,300
+26% +$1.6M 0.66% 59
2022
Q2 		$4.99M Buy
+127,010
New +$5.11M 0.56% 52

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Atika Capital Management's CYTK Position: Q2 2024 in Review

Atika Capital Management sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 70,000 shares — an estimated $4.91M sold.

Atika Capital Management first reported a position in CYTK in Q2 2022 and held it in 6 quarters. The position peaked at $7.77M in Q3 2022. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Atika Capital Management reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Atika Capital Management sold 70,000 Cytokinetics shares in Q2 2024, an estimated $4.91M.
  • Atika Capital Management first reported a position in Cytokinetics in Q2 2022 and held it in 6 quarters.
  • Atika Capital Management's Cytokinetics position peaked at $7.77M in Q3 2022.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Atika Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.